UB Paderborn / Katalog / Suche / in CDI

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Journal of medicinal chemistry, 2019-10, Vol.62 (20), p.8973-8995

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19

Drug metabolism and disposition, 2012-09, Vol.40 (9), p.1698

2012

Link zum Volltext

Verfügbarkeit prüfen

Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development

The AAPS journal, 2013-07, Vol.15 (3), p.717-727

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

Dermatology and therapy, 2023-12, Vol.13 (12), p.3153-3164

2023

Link zum Volltext

Verfügbarkeit prüfen

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

CPT: pharmacometrics and systems pharmacology, 2018-03, Vol.7 (3), p.135-146

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of Methylprednisolone and Its Liver-Targeted Dextran Prodrug on Ischemia-Reperfusion Injury in a Rat Liver Transplantation Model

Pharmaceutical research, 2007-12, Vol.24 (12), p.2231-2238

2007

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans

European journal of pharmaceutical sciences, 2021-10, Vol.165, p.105928-105928, Article 105928

2021

Link zum Volltext

Verfügbarkeit prüfen

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Dermatology and therapy, 2021-10, Vol.11 (5), p.1763-1776

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of duration of ischemia and donor pretreatment with methylprednisolone or its macromolecular prodrug on the disposition of indocyanine green in cold-preserved rat livers

Pharmaceutical research, 2004-06, Vol.21 (6), p.1000-1008

2004

Link zum Volltext

Verfügbarkeit prüfen

Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2

Journal of medicinal chemistry, 2021-01, Vol.64 (1), p.677-694

2021

Link zum Volltext

Verfügbarkeit prüfen

Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: Local immunosuppressive effects in liver after systemic administration to rats

Pharmaceutical research, 2003-02, Vol.20 (2), p.198-204

2003

Link zum Volltext

Verfügbarkeit prüfen

Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone

Transplantation, 2006-03, Vol.81 (5), p.678

2006

Link zum Volltext

Verfügbarkeit prüfen

Attenuation of Kupffer cell activation in cold-preserved livers after pretreatment of rats with methylprednisolone or its macromolecular prodrug

Pharmaceutical research, 2003-07, Vol.20 (7), p.1001-1008

2003

Link zum Volltext

Verfügbarkeit prüfen

Antibody Drug-Target Engagement Measurement in Tissue Using Quantitative Affinity Extraction Liquid Chromatography–Mass Spectrometry: Method Development and Qualification

Analytical chemistry (Washington), 2017-05, Vol.89 (9), p.5115-5123

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of 40 kDa PEG in rodents using high-field NMR spectroscopy

Journal of pharmaceutical and biomedical analysis, 2019-07, Vol.171, p.30-34

2019

Link zum Volltext

Verfügbarkeit prüfen

High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002-05, Vol.772 (1), p.107-114

2002

Link zum Volltext

Verfügbarkeit prüfen

Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans

Clinical pharmacology in drug development, 2023-10, Vol.12 (10), p.956-965

2023

Link zum Volltext

Verfügbarkeit prüfen

Hepatic disposition of cyclosporine A in isolated perfused rat livers

Journal of pharmacy & pharmaceutical sciences, 2004-02, Vol.7 (1), p.47-54

2004

Link zum Volltext

Verfügbarkeit prüfen

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects

Clinical pharmacology in drug development, 2022-04, Vol.11 (4), p.442-453

2022

Link zum Volltext

Verfügbarkeit prüfen

Microsomal cytochrome P450 levels and activities of isolated rat livers perfused with albumin

Pharmaceutical research, 2003, Vol.20 (1), p.81-88

2003

Link zum Volltext

Verfügbarkeit prüfen

Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide

Journal of medicinal chemistry, 2017-05, Vol.60 (9), p.3795-3803

2017

Link zum Volltext

Verfügbarkeit prüfen

LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin

Bioanalysis, 2016-02, Vol.8 (3), p.193-204

2016

Link zum Volltext

Verfügbarkeit prüfen

Development and characterization of a free therapeutic ligand binding assay with assistance from kinetics modeling

Journal of immunological methods, 2015-04, Vol.419, p.18-24

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19

Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Effects of Methylprednisolone and Its Liver-Targeted Dextran Prodrug on Ischemia-Reperfusion Injury in a Rat Liver Transplantation Model

Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Effects of duration of ischemia and donor pretreatment with methylprednisolone or its macromolecular prodrug on the disposition of indocyanine green in cold-preserved rat livers

Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2

Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: Local immunosuppressive effects in liver after systemic administration to rats

Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone

Attenuation of Kupffer cell activation in cold-preserved livers after pretreatment of rats with methylprednisolone or its macromolecular prodrug

Antibody Drug-Target Engagement Measurement in Tissue Using Quantitative Affinity Extraction Liquid Chromatography–Mass Spectrometry: Method Development and Qualification

Pharmacokinetics of 40 kDa PEG in rodents using high-field NMR spectroscopy

High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard

Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans

Hepatic disposition of cyclosporine A in isolated perfused rat livers

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects

Microsomal cytochrome P450 levels and activities of isolated rat livers perfused with albumin

Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir

Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide

Discovery of 5‑Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)‑one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119

LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin

Development and characterization of a free therapeutic ligand binding assay with assistance from kinetics modeling

Suchergebnisse filtern